At the time of announcing its first-quarter 2016 results, Endo provided a dismal guidance for 2016 due to several headwinds including greater-than-expected price erosion across the Generics sector, delays on regulatory actions related to certain Endo products and an earlier-than-expected generic entrant for Voltaren Gel.